非霍奇金淋巴瘤

预约门诊

分期

如果确诊非霍奇金淋巴瘤，下一步是确定这种癌症的严重程度（分期）。影像学检查、血液检测和活检可用于确定非霍奇金淋巴瘤的分期。医疗护理团队会使用癌症分期来帮助制定治疗计划。

非霍奇金淋巴瘤的分期范围为 1 期至 4 期：

  • 1 期非霍奇金淋巴瘤。 在此分期，仅单个淋巴结区域或单个淋巴结外部位受累。
  • 2 期非霍奇金淋巴瘤。 2 期是指横膈膜同侧的两个或两个以上淋巴结区域受累。
  • 3 期非霍奇金淋巴瘤。 3 期是指横膈膜两侧的淋巴结区域受累，或横膈膜上方的淋巴结及脾脏均受累。
  • 4 期非霍奇金淋巴瘤。 4 期是指非霍奇金淋巴瘤已扩散至淋巴系统以外的器官。

非霍奇金淋巴瘤预后

癌症预后反映癌症可被治疗或治愈的可能性。预后可能取决于以下因素：

  • 您的年龄。
  • 您的整体健康状况。
  • 您所患的非霍奇金淋巴瘤类型。
  • 癌症分期。
  • 您的血液检测结果。

如果您想了解治疗后的情况，请与医疗护理团队讨论您的预后。医疗护理团队的成员可以解释在评估您的预后时会考虑哪些因素。

申请预约
诊断与治疗生存率
Nov. 07, 2025

Living with 非霍奇金淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

mjlandin
Does anyone else have MGUS?

1135 Replies Sat, Jan 31, 2026

lindagi
AML successful treatment

75 Replies Sat, Jan 31, 2026

jak2mpnpositive
I have JAK2 ET and MPN: Anyone else have these symptoms?

111 Replies Sat, Jan 31, 2026

See more discussions
  1. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024.
  2. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024.
  3. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024.
  4. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024.
  5. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024.
  6. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024.
  7. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024.
  8. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1.
  9. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042.
  10. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6.
  11. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  12. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025.
  13. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025.
  14. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025.
  15. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  16. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025.
  17. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025.

相关

相关医疗程序

Mayo Clinic 新闻

产品与服务

非霍奇金淋巴瘤